A New Tool for Monitoring Asthma Outcomes: the ITG Asthma Short Form
Overview
Rehabilitation Medicine
Affiliations
Background: Asthma treatment has broadened from managing clinical markers to incorporate factors that are most meaningful to patients, collectively called health-related quality of life (HQL).
Objective: To develop an asthma-specific HQL tool, meeting demands for brevity, usefulness and measurement precision.
Methods: The 20-item Sydney Asthma Quality of Life Questionnaire (AQLQ) and six additional items were studied using factor analysis, reliability and validity tests among asthma patients 14 and older.
Results: The 15-item Integrated Therapeutics Group Asthma Short Form (ITG-ASF) retains the validity of the AQLQ with improved scaling properties and interpretability. The ITG-ASF yields 6 scores: Symptom-Free Index, Functioning with Asthma, Psychosocial Impact of Asthma, Asthma Energy and Asthma-Confidence in Health and a Total. All items correlated 0.40 or higher with their hypothesized scales and passed discriminant validity tests, with scaling success rates from 75 to 100%. Reliability exceeded the minimum of 0.70 for group comparisons. Ceiling and floor effects were acceptable. Scales were valid in relation to changes in asthma severity and lung function. The best predictor of asthma severity (National Asthma Education and Prevention Program (NAEPP) staging) was the Symptom-Free Index. A Spanish translation is available, Chinese-American is forthcoming. The reading grade level is 4.8.
Conclusions: Development of the ITG-ASF was a data-driven process maximizing measurement precision and breadth while minimizing burden. The ITG-ASF is a brief, comprehensive and empirically valid tool that complements traditional markers of the outcomes of asthma care.
Improving CKD-Specific Patient-Reported Measures of Health-Related Quality of Life.
Ware Jr J, Richardson M, Meyer K, Gandek B J Am Soc Nephrol. 2019; 30(4):664-677.
PMID: 30898870 PMC: 6442339. DOI: 10.1681/ASN.2018080814.
Kaambwa B, Chen G, Ratcliffe J, Iezzi A, Maxwell A, Richardson J Pharmacoeconomics. 2016; 35(1):111-124.
PMID: 27557995 DOI: 10.1007/s40273-016-0446-4.
Apfelbacher C, Paudyal P, Bulbul A, Smith H Syst Rev. 2014; 3:83.
PMID: 25060719 PMC: 4124509. DOI: 10.1186/2046-4053-3-83.
Edelen M, Stucky B, Sherbourne C, Eberhart N, Lara M Clin Ther. 2014; 36(5):680-8.
PMID: 24813430 PMC: 4078985. DOI: 10.1016/j.clinthera.2014.04.007.
Assessing the validity of the RAND negative impact of asthma on quality of life short forms.
Sherbourne C, Stucky B, Edelen M, Eberhart N, Kleerup E, Lara M J Allergy Clin Immunol. 2014; 134(4):900-7.
PMID: 24746752 PMC: 4186891. DOI: 10.1016/j.jaci.2014.03.002.